Business
Concordance of Parsortix with tissue biopsy
Concordance of Parsortix with tissue biopsy.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 5460Y\n Angle PLC\n 17 January 2022\n \n \n \n \n \n \n \n For immediate release\n \n \n \n \n 17 January 2022\n \n \n \n \n \n \n \n \n ANGLE plc (\"the Company\")\n \n \n \n \n \n BREAKTHROUGH STUDY DEMONSTRATES FOR THE FIRST TIME CONCORDANCE OF PARSORTIX LIQUID BIOPSY BLOOD TEST WITH INVASIVE TISSUE BIOPSY OF THE METASTATIC SITE\n \n \n \n \n \n Study explores key unmet medical need for metastatic breast cancer as over 50% of patients fail to receive successful tissue biopsies of the metastatic site preventing access to essential information to guide their treatment\n \n \n \n \n \n Potential for Parsortix liquid biopsy blood test as an alternative to invasive surgical tissue biopsy in metastatic breast cancer\n \n \n \n \n \n ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is delighted to announce the publication of breakthrough research undertaken by the world-class team at the University of Southern California Norris Cancer Center. The research demonstrates the potential of circulating tumour cells (CTCs) harvested from a simple blood draw using the Company's Parsortix® system to be used as an alternative to invasive metastatic tissue biopsy for metastatic breast cancer (MBC) patients.\n \n \n \n \n \n In the United States, guidelines published by the National Comprehensive Cancer Network (NCCN) recommend a tissue biopsy of a secondary cancer site in MBC because of the critical need for up-to-date information on cancer progression to guide treatment decisions. However, over 50% of all MBC patients do not have a successful metastatic tissue biopsy because they are either too ill for the invasive procedure, the cancer site is inaccessible and/or insufficient tissue is available. Hence, there is nothing to guide ongoing treatment decisions in these patients. Even in those patients who can undergo a metastatic tissue biopsy, there is rarely the option for a second such biopsy, yet the cancer continues to evolve, often to multiple sites. A simple, repeatable liquid biopsy alternative using the Parsortix system could resolve the issues with metastatic tissue biopsies and, as the study finds, provide real time information on the cancer evolution to guide treatment options.\n \n \n \n \n \n The study was the first of its kind to direct...